One of the most common birth defects worldwide is hearing loss. Every 1,000 babies born worldwide are affected by permanent hearing loss in one or both ears. Hearing loss can significantly affect a baby's development.
CapitalBiotech has developed the Hereditary Deafness Gene Detection Assay using semiconductor sequencing technology. It can identify 100 mutant sites on 18 deafness-related genes such as GJB2, SLA26A4, GJB3, MT-RNR1, and others. This detection assay boasts an accuracy of over 99.9%.
The BioElectron Gene Squencer 4000 platform was developed in collaboration with Thermo Fisher. It can detect 384 samples simultaneously.
Development Status and Future of In Vitro Diagnostic TechnologyDecember 15, 2022In vitro diagnostic technology refers to products and services that obtain relevant clinical diagnostic information by testing samples of the body including blood, body fluids, and tissues outside the...view
Breaking Barriers: Innovations in Gynecologic Cancer TreatmentJune 26, 2023Gynecologic cancers, which include ovarian, uterine, cervical, vaginal, and vulvar cancers, affect thousands of women worldwide. The diagnosis of gynecologic cancer can be devastating, but thanks to o...view
A Deep Dive into CapitalBiotech's LuxScan TechnologyFebruary 8, 2024Microarrays have revolutionized the field of life sciences, enabling researchers to analyze thousands of genes simultaneously. This technology underpins advancements in various fields, from drug disco...view
Microarray Platforms with Various Applications in Genetic ResearchJuly 18, 2024In recent years, the advancements in genetic research have revolutionized our understanding of the human genome. At the forefront of these developments is the Microarray Platform, a pivotal technology...view